Cargando…

Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection

Background: Dynamics of antibody responses were investigated after a SARS-CoV-2 outbreak in a private company during the first wave of the pandemic. Methods: Workers of a sewing company (Lithuania) with known SARS-CoV-2 RT-PCR result during the outbreak (April 2020) were invited to participate in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kučinskaitė-Kodzė, Indrė, Simanavičius, Martynas, Šimaitis, Aistis, Žvirblienė, Aurelija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622371/
https://www.ncbi.nlm.nih.gov/pubmed/34835119
http://dx.doi.org/10.3390/v13112313
_version_ 1784605678055194624
author Kučinskaitė-Kodzė, Indrė
Simanavičius, Martynas
Šimaitis, Aistis
Žvirblienė, Aurelija
author_facet Kučinskaitė-Kodzė, Indrė
Simanavičius, Martynas
Šimaitis, Aistis
Žvirblienė, Aurelija
author_sort Kučinskaitė-Kodzė, Indrė
collection PubMed
description Background: Dynamics of antibody responses were investigated after a SARS-CoV-2 outbreak in a private company during the first wave of the pandemic. Methods: Workers of a sewing company (Lithuania) with known SARS-CoV-2 RT-PCR result during the outbreak (April 2020) were invited to participate in the study. Virus-specific IgG and IgM were monitored 2, 6 and 13 months after the outbreak via rapid IgG/IgM serological test and SARS-CoV-2 S protein-specific IgG ELISA. Results: Six months after the outbreak, 95% (CI 86–99%) of 59 previously infected individuals had virus-specific antibodies irrespective of the severity of infection. One-third of seropositive individuals had virus-specific IgM along with IgG indicating that IgM may persist for 6 months. Serological testing 13 months after the outbreak included 47 recovered individuals that remained non-vaccinated despite a wide accessibility of COVID-19 vaccines. The seropositivity rate was 83% (CI 69–91%) excluding one case of confirmed asymptomatic reinfection in this group. Between months 6 and 13, IgG levels either declined or remained stable in 31 individual and increased in 7 individuals possibly indicating an exposure to SARS-CoV-2 during the second wave of the pandemic. Conclusions: Detectable levels of SARS-CoV-2-specific antibodies persist up to 13 months after infection for the majority of the cases.
format Online
Article
Text
id pubmed-8622371
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86223712021-11-27 Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection Kučinskaitė-Kodzė, Indrė Simanavičius, Martynas Šimaitis, Aistis Žvirblienė, Aurelija Viruses Article Background: Dynamics of antibody responses were investigated after a SARS-CoV-2 outbreak in a private company during the first wave of the pandemic. Methods: Workers of a sewing company (Lithuania) with known SARS-CoV-2 RT-PCR result during the outbreak (April 2020) were invited to participate in the study. Virus-specific IgG and IgM were monitored 2, 6 and 13 months after the outbreak via rapid IgG/IgM serological test and SARS-CoV-2 S protein-specific IgG ELISA. Results: Six months after the outbreak, 95% (CI 86–99%) of 59 previously infected individuals had virus-specific antibodies irrespective of the severity of infection. One-third of seropositive individuals had virus-specific IgM along with IgG indicating that IgM may persist for 6 months. Serological testing 13 months after the outbreak included 47 recovered individuals that remained non-vaccinated despite a wide accessibility of COVID-19 vaccines. The seropositivity rate was 83% (CI 69–91%) excluding one case of confirmed asymptomatic reinfection in this group. Between months 6 and 13, IgG levels either declined or remained stable in 31 individual and increased in 7 individuals possibly indicating an exposure to SARS-CoV-2 during the second wave of the pandemic. Conclusions: Detectable levels of SARS-CoV-2-specific antibodies persist up to 13 months after infection for the majority of the cases. MDPI 2021-11-19 /pmc/articles/PMC8622371/ /pubmed/34835119 http://dx.doi.org/10.3390/v13112313 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kučinskaitė-Kodzė, Indrė
Simanavičius, Martynas
Šimaitis, Aistis
Žvirblienė, Aurelija
Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
title Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
title_full Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
title_fullStr Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
title_full_unstemmed Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
title_short Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection
title_sort persistence of sars-cov-2-specific antibodies for 13 months after infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622371/
https://www.ncbi.nlm.nih.gov/pubmed/34835119
http://dx.doi.org/10.3390/v13112313
work_keys_str_mv AT kucinskaitekodzeindre persistenceofsarscov2specificantibodiesfor13monthsafterinfection
AT simanaviciusmartynas persistenceofsarscov2specificantibodiesfor13monthsafterinfection
AT simaitisaistis persistenceofsarscov2specificantibodiesfor13monthsafterinfection
AT zvirblieneaurelija persistenceofsarscov2specificantibodiesfor13monthsafterinfection